Recruiting

Residual Exacerbations With Mepolizumab

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

ClinicalTrials.gov IDNCT04578171

PhaseNot Applicable

Enrollment60

SponsorLaval University

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Asthma

About this study

Interventions

Drug: Mepolizumab — 100 mg subcutaneous injections every four weeks

Primary outcomes

Proportion of eosinophilic vs non-eosinophilic remaining exacerbation during the treatment period (Between baseline and month 24)

Eligibility information

Inclusion Criteria: * With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society * Eligible for mepolizumab treatment * Able and willing to sign the informed consent form Exclusion Criteria: * Any respiratory disease apart from asthma * Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome

Study locations

Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec G6K 1L8 Canada

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.